Laimei Pharmaceutical (300006.SZ), which was determined to deploy in the field of ophthalmology, was given a heavy blow.
On July 19, Laimei Pharmaceutical announced that the company and Wuhan Youzhiyou Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as “Youzhiyou Bio”) are researching and developing The strategic cooperation agreement signed by the ophthalmic drug Y400 of the company has been terminated.
Red Star Capital Bureau noticed that ophthalmology, as a key product area of Lai Mei Pharmaceutical, has established a joint venture company with Aier Ophthalmology (300015.SZ), and in 2021 Realized the “myopia magic medicine” low-concentration atropine was marketed and sold in Aier Eye Hospital.
The product business layout is “cross-cut”< /strong>
The cooperation agreement signed for nearly two years has been terminated. Lamei Pharmaceutical announced yesterday that it will terminate the cooperation with Youzhiyou Bio on the priority sales agency of the ophthalmic drug Y400 protocol.
As early as September 2020, the two parties signed the “Strategic Cooperation Agreement”, stipulating that Youzhiyou Biotechnology will use its ophthalmic drug Y400 wet macular degeneration (nAMD) under research and development. The priority sales agency rights of bispecific antibody drugs in China are granted to Lamei Pharmaceutical or designated affiliates.
Nowadays, Youzhiyou Bio has broken the agreement and plans to enter into a contract with a pharmaceutical company for Y400 (because the confidentiality responsibilities of Laimei Pharmaceutical have not been disclosed to a third party, hereinafter referred to as the “pharmaceutical company” Instead) to carry out business cooperation, Lai Mei Pharmaceutical also received corresponding compensation for being “stabbed horizontally” by the pharmaceutical company.
The termination of the agreement states that if Youzhiyou Bio and a pharmaceutical company or any third party reach a cooperation agreement on Y400, youzhiyou Biologics will pay 20% of the sales milestone payments on Y400 it expects to receive from the pharmaceutical company or any third party in the future as compensation to Lai Mei Pharmaceutical.
In addition, Youzhiyou Bio agreed to select a product recognized by both parties in its follow-up R&D pipeline and continue to grant it to Laimei Pharmaceutical. Priority sales agency rights under the same conditions in China.
On July 20, the Red Star Capital Bureau called the Securities Department of Laimei Pharmaceuticals regarding the specific reasons for the termination of the agreement between the two parties, but it was unclear. Subsequently, the Red Star Capital Bureau contacted the public phone number of Youzhiyou Bio, but it was not connected as of press time.
Ophthalmic drugs are the key products to be introduced
Development with Aier Ophthalmology “Myopia Magic Medicine” in-depth cooperation
Red Star Capital Bureau read the annual report of Lai Mei Pharmaceutical and noticed that in addition to anti-tumor and digestive tract, ophthalmology-related fields are also its strategic layout important part of. It said that in 2022, the company will also continue to focus on thyroid, digestive tract, ophthalmology, medical devices and other fields, with a view to building a leading enterprise in the segment.
However, from the performance point of view, the operation of Laimei Pharmaceuticals is still under pressure. In 2021, Lai Mei Pharmaceutical achieved revenue of 1.225 billion yuan, a year-on-year decrease of 22.63%; net profit attributable to shareholders of listed companies was -100 million yuan. Red Star Capital Bureau noticed that before the cooperation agreement with Youzhiyou Bio was broken, Laimei Pharmaceuticals had in-depth cooperation with Aier Ophthalmology.
In 2021, Laimei Pharmaceutical and Aier Ophthalmology will establish a joint venture company Hunan Maiou Medical Technology Co., Ltd. (hereinafter referred to as “Maio Medical”), Maiou Medical and Changsha Atropine sulfate eye drops jointly developed by Aier Eye Hospital was approved.
Laimei Pharmaceutical said that it has achieved low-concentration atropine sales in Aier Eye Hospital in 2021, and has opened up online sales channels, and the next step will be to break through the region To avoid limitations, expand the nationwide promotion of products. At the same time, the company will continue to develop or introduce a series of ophthalmic drugs and care products such as dry eye with the help of the hospital system of Aier Eye Hospital, and gradually form a cluster of ophthalmic drug products.
At that time, Lai Mei Pharmaceutical also mentioned separately in an investor conference call in February 2021 that for its future layout in the field of ophthalmology, “
span>The company has invested in Youzhiyou Bio through the industry fund, and obtained the priority sales agency right of its wet macular degeneration bispecific antibody drug Y400 in China.” As everyone knows, a year later, others have intervened, which also means that the original ophthalmic product layout has been disrupted.
However, after the termination of the agreement, Lamei Pharmaceutical also stated that the parties had actively communicated and negotiated the details of the cooperation-related matters according to the progress of the project, but had not signed the substantive agreement. formal agreement.
Red Star News reporter Deng Lingyao
Editor Yang Cheng